Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Hyperlactatemia and concurrent use of antiretroviral therapy among HIV infected patients in Uganda

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Waiswa, M.
dc.contributor.author Byarugaba, B.
dc.contributor.author Ocama, P.
dc.contributor.author Mayanja-Kizza, H.
dc.contributor.author Seremba, E.
dc.contributor.author Ganguli, S.
dc.contributor.author Crowther, M.
dc.contributor.author Colebunders, R.
dc.date.accessioned 2014-04-04T08:32:22Z
dc.date.available 2014-04-04T08:32:22Z
dc.date.issued 2012
dc.identifier.issn 1680-6905
dc.identifier.doi http://dx.doi.org/10.4314/ahs.v12i3.4
dc.identifier.other ITG-CLA
dc.identifier.other DCS
dc.identifier.other U-HIVCLI
dc.identifier.other JIF
dc.identifier.other DOI
dc.identifier.other E-only
dc.identifier.other Abstract
dc.identifier.other FTA
dc.identifier.uri http://hdl.handle.net/10390/7460
dc.description.abstract BACKGROUND: We determined the prevalence and factors associated with hyperlactatemia among HIV patients admitted on the emergency ward of a national hospital in Uganda. OBJECTIVE: We were specifically interested in knowing whether there was an association between clinically significant hyperlactatemia and concurrent antiretroviral therapy (ART) use. METHODS: A cross sectional descriptive study enrolled 303 HIV infected patients at a national referral hospital between March and April 2008. We consecutively recruited all eligible HIV infected patients above 18 years admitted on the emergency ward. Data were collected on socio-demographic, clinical and laboratory characteristics. Lactate levels were measured using the Accutrend(R) portable lactate analyser. Data analysis was performed using Stata 10.0; P-value of < 0.05 was considered to be significant. RESULTS: Three hundred and three HIV infected patients were recruited. Prevalence of hyperlactatemia (lactate >/=2.5mmol/L) was 252 (83.2%). Clinically significant hyperlactatemia (lactate >/=4mmol/L) was present in 105/303(34.6%) patients. There was no association between use of ART and clinically significant hyperlactatemia. In the multivariate analysis, body weakness 1.91 (1.09-3.35), skin rash 3.18 (1.11-9.10) and tachypnoea 1.04 (1.01-1.07) were independently associated with clinically significant hyperlactatemia. CONCLUSION: There was a high prevalence of clinically significant hyperlactatemia among HIV infected patients but it was not associated with concurrent antiretroviral use. en_US
dc.language English en_US
dc.subject Viral diseases en_US
dc.subject HIV en_US
dc.subject AIDS en_US
dc.subject HAART en_US
dc.subject Antiretrovirals en_US
dc.subject Prevalence en_US
dc.subject Risk factors en_US
dc.subject Associations en_US
dc.subject Hyperlactatemia en_US
dc.subject Emergency care en_US
dc.subject Hospitalization en_US
dc.subject Predictors en_US
dc.subject Body weakness en_US
dc.subject Tachypnoea en_US
dc.subject Rashes en_US
dc.subject Uganda en_US
dc.subject Africa, East en_US
dc.title Hyperlactatemia and concurrent use of antiretroviral therapy among HIV infected patients in Uganda en_US
dc.type Article-E en_US
dc.citation.issue 3 en_US
dc.citation.jtitle African Health Sciences en_US
dc.citation.volume 12 en_US
dc.citation.pages 268-275 en_US
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/23382739
dc.citation.jabbreviation Afr Health Sci en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record